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1 Introduction
The etiology of fetal bradycardia following para-
cervical block (PCB) is not clear. Vasoconstriction
of the uterine arteries, hypertonus of the uterus,
and the direct toxic effect of a local anesthetic
agent on the fetus or a combination of the above
have been presented as etiological factors [17]. To
reduce fetal side-effects, a superficial and low
dosage technique has been advised by BLOOM
[2] and JÄGERHORN [10]. By this method it may
be possible to decrease the rate of the absorption
of an anesthetic agent from the highly vascular
paracervical space.
Since there is no consistent information about the
maternal and fetal effects of this kind of PCB, we
have studied the fetal heart rate patterns (FHR),
uterine activity, placental blood flow, and fetal
acid-base balance in connection with such a block.
In addition, we measured the actual maternal, fetal
and neonatal plasma bupivacaine levels.
2 Materials and methods
2.1 Patients: Thirty-eight patients, who had an
uncomplicated pregnancy, were between the
39—41 weeks of gestation and in active labor with
the fetus in cephalic presentation were studied. In
three cases a second PCB was used approximately
two hours after the first block, so the material
number includes in total 41 PCBs. The age of the
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patients varied from 18 to 28 years (mean ± SD,
24.3 ± 3.7), and the parity from 1 to 3 (1.6 ± 0.5).
The mean duration of the labor was 10 hours
52 minutes ± 3 hours 37 minutes and the mean
period from PCB to delivery 2 hours 24 minutes
± 1 hour 19 minutes. The mean weight of the
babies was 3,565 ± 352 grams and all but one had
APGAR scores of 8 or better at 1,5 and 15 minutes.
The one exception was a baby who had 3/6/8
scores at 1,5 and 15 minutes and was delivered by
vacuum extraction because of bradycardia in the
second stage of labor, 4 hours 32 minutes after
PCB. Another baby was also delivered by vacuum
extraction due to prolongation of the second stage
2 hours and 12 minutes after PCB but was in
excellent condition after delivery. One cesarean
section was performed 8 hours after PCB because
of persistent occiput posterior presentation.
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2.2 Paracervical block: The block was performed
when the patient had painful contractions and the
cervix was dilated 4 to 7 cm. During the procedure
the patient was in the left lateral (tilted 30°)
position, and after PCB she was turned into a
totally lateral position. During and 30 minutes
after the procedure, the patient received 500 ml of
RINGER solution. The patient's heart rate and
blood pressure were recorded before the PCB
and at three minutes intervals during the first
30 minutes after the block. Bupivacaine with a
total dose of 10 ml (25 mg) of 0.25 % solution was
used. Five ml of the solution was injected with a
KOBAK's needle to each lateral fornix and the
depth of the injection was limited to no more than
3mm.
2.3 Fetal heart rate (FHR) monitoring: At least
30 minutes before PCB the membranes were
ruptured if not already ruptured, and the FHR of
the fetuses were directly monitored using a scalp
electrode during a control period of at least
20 minutes before PCB and thereafter until
delivery. The details of the FHR pattern were
analyzed visually. The decelerations were classified
according to HON [7]. Baseline variability was eval-
uated by the maximum amplitudes for 1-minutes
periods. An amplitude less than 5 beats per minute
for more than 5 minutes was regarded as being of
the silent type. Acceleration was defined as an
increase of FHR from baseline by more than
15 beats in less than 30 seconds. Bradycardia was
defined as a decrease of mean FHR of at least
20 bpm or an absolute rate less then 100 bpm and
of a duration greater than two minutes. Baseline,
baseline variability, the number of different
decelerations (early, late, variable), accelerations
and the occurrence and duration of bradycardia
were determined for each ΙΟ-minute period
during the 20 minute prior PCB and 30 minute
after the block.
2.4 Uterine activity: In eleven patients the intra-
uterine pressure was measured using an open-
ended transcervical intrauterine catheter con-
nected to a strain gauge placed at the level of the
sternum. In these patients the baseline uterine
tone, frequency, and amplitude of contractions
(measured in MONTEVIDEO units) were recorded
during a 20 minute control period and 30 minute
observation period after PCB. In other patients
frequency and relative change in amplitude of
contractions were measured by external toco-
graphy.
2.5 Placental blood flow: Both intervillous and
myometrial blood flow was measured in ten
patients with the placenta at the anterior wall of
the uterus just before and 10 minutes after PCB.
These patients remained in the tilted left laterally
position from PCB until the second measurement.
The placental blood flow in ml/min/100 ml of the
intervillous space was measured by 133Xe-washout
method described in detail elsewhere [15].
2.6 Bubivacaine concentrations: Blood samples
for the determination of the plasma bupivacaine
concentration were taken from a maternal vein
and the fetal scalp 20 minutes after PCB and at
delivery from a maternal vein and the umbilical
artery and vein. The plasma bupivacaine concen-
trations were measured with a specific gas-liquid-
chromatographic method [11].
2.7 Fetal acid-base balance: A fetal scalp sample
and umbilical venous and arterial blood samples
were obtained in 14 cases. The actual pH was
immediately determined according to the method
of S AUNG just before the. PCB and 15 to 20
minutes after PCB and at delivery.
2.8 Statistics: STUDENT'S t-test and Chi-Square-
test were used for the statistical analyses of the
results.
3 Results
3.1 Maternal effects: The analgesic effect of a
single PCB as assessed by the patients was good in
31 cases (76%), "moderately good" in 5 cases
(12%), and "poor" in 5 cases (12%). The duration
of the PCB varied from one to two hours. The
maternal heart rate was 80 ± 11 bpm before and
85 ± 7 after the PCB on average. Systolic blood
pressure was correspondingly 131 ±21 mmHg and
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Tab. I. Changes in fetal heart rate pattern before and after paracervical block with 25 mg of bupivacaine (N = 41)
Control period
before block
Basal rate, bpm (mean ± SO)
Variability, bpm
Disappearance of FHR accelerations (n: of patients)
Bradycardia
Silent pattern
Early or variable decelerations (< 30 bpm)

















































* = ρ < 0.05
** = ρ < 0.01 I vs. control period (t-test or X2-test)
p<0.001
Fig. 1. An example of the fetal bradycardia and acidosis following paracervical block. Note the apparent increase in
uterine tone and loss of beat-to-beat variation after the bradycardia episode.
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diastolic 82 ± 15 mmHg before PCB and 125 ± 20
and 82 ±11 after PCB (p>0.05). No cases of
hypotension (fall of the blood pressure by 20 % or
more) were recorded and no local or systemic
side-effects of bupivacaine were observed.
3.2 Fetal heart rate pattern: The results are
summarized in Tab. I
The mean basal fetal heart rate during the
10 minute periods did not change significantly.
The baseline fetal heart rate variability decreased
significantly during the period from 10 minutes
through 20 minutes after PCB. Recordings without
FHR accelerations were noticed only once during
the control period but 11 times (27 %) (p < 0.001)
during the second and 6 times (15%) (p < 0.01)
during the third observation period after PCB.
Bradycardia was not observed during the control
period but appeared in 12% of the cases (p<0.01)
after PCB. One case demonstrating fetal brady-
cardia is presented in Fig. 1. Fetal heart rate
decelerations of early or variable type more than
30 bpm appeared significantly (p < 0.05) more
often during the first observation period than
during the control time. Late decelerations (4 and
5 during the first and second observation periods,
respectively) occurred only after PCB. No cases of
silent pattern were noticed during the control
period but appeared in 20 % of the cases after the
block (p < 0.05).
3.3 Bupivacaine concentrations: Mean maternal
bupivacaine concentration 20 minutes after PCB
was 0.14±0.06ug/ml and 0.07 ± 0.04 at birth.
Simultaneous fetal, umbilical venous and arterial
concentrations were correspondingly 0.04 ±0.02,
0.03 ± 0.01 and 0.03 ± 0.01 ug/ml and they were
significantly (p < 0.001) lower than the respec-
tive maternal concentrations. Individual maternal
and fetal concentrations and their changes at
20 minutes after PCB and at delivery are shown
in Figs. 2, 3 and 4. One episode of bradycardia
occurred in these eleven cases (indicated in Fig.4).
3.4 Placental blood flow: The mean myometrial
blood flow was 9.0±5.0 before and 10.4±9.0ml/
min/100 g after PCB. Mean intervillous flow











* ^TIME FROM PCB TO DELIVERY20 min
after PCB
Fig. 2. Maternal plasma bupivacaine concentrations after
paracervical block with 25 mg of bupivacaine. Closed
circles represent values 20 minutes after the block and














^TIME FROM PCB TO DELIVERY20 mi n
after PCB
Fig. 3. Fetal plasma levels of bupivacaine after para-
cervical block with 25 mg of bupivacaine. Closed circles
represent concentrations in fetal scalp blood 20 minutes
after the block and open circles concentrations in umbili-
cal artery blood.
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Fig. 4. Correlation of maternal and fetal bupivacaine
levels 20 minutes after PCB and at delivery. The asterix
indicates one case with fetal bradycardia.
respectively (p > 0.05). Individual measurements
are shown in Fig. 5 in which three cases with
pathological FHR pattern are illustrated. The
changes in the IVBF were minimal in these cases
also.
3.5 Uterine activity: No significant changes in
uterine tone, amplitude and frequency of contrac-
tions were observed after PCB. Mean Montevideo
units were 155 ± 12 before and 150 ±20, 152 ±12,
165 ± 15 during the three ten minute-periods after
PCB (p > 0.05). An obvious hypertonus of the
uterus after PCB was observed in three cgses of
bradycardia but not in the other two cases of
bradycardia, in the eight cases of silent FHR
pattern or in nine cases of late decelerations.
3.6 Fetal acid-base balance: Mean actual fetal pH
from the scalp capillary blood just before PCB was
7.33 ±0.05 and 7.31 ±0.03 20 minutes after
I V B F










Fig. 5. Intervillous blood flow as measured by 133Xenon
washout method before and after paracervical block with















U M B I L I C A L
ARTERY
Fig. 6. The actual pH in fetal scalp before and after PCB
and in umbilical artery immediately after delivery. The
asterix indicate cases with fetal bradycardia.
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PCB (p > 0.05). Individual fetal scalp pH values as
well as mean umbilical arterial values (2 hours
20 minutes after PCB) are shown in Fig. 6. In
three cases of bradycardia the mean fetal pH
was 7.28 after PCB. Mean pH from umbilical
venous blood was 7.27 ± 0.08 and arterial blood
7.36 ±0.09.
4 Discussion
In spite of extensive clinical experience and
research work, the usefulness and safety of PCB is
still a matter of controversy [9, 17]. To reduce
fetal hazards, a low dosage, superficial technique
of PCB has been advised by BLOOM [2] and by
JÄGERHORN [10] and was also used in our study.
The success rate (76%) and the failure rate (12%)
we found using that technique are of a similar
order to that reported when using larger bupi-
vacaine dosages [17]. The plasma levels of bupi-
vacaine after low dosage (25 mg) administration in
maternal, fetal and neonatal blood are lower than
reported by HYMAN [8] (maternal 0.14, neonatal
0.08ug/ml) or by BEAZLEY [1] (1.07 and 0.10),
who used 50 mg of bupivacaine at PCB. No results
of plasma bupivacaine concentration in connection
with the present low dosage PCB have been
published. On the other hand, in connection with
epidural analgesia using 25 mg of bupivacaine
correspondingly low levels have been observed
[11]. The maternal-fetal ratios of bupivacaine after
PCB or at delivery are in our results very similar to
earlier studies using bupivacaine in PCB [1, 8] or in
epidural blocks [11]. Thus, it thus seems possible
to decrease fetal and maternal levels of bupi-
vacaine by using a low dosage and by superficial
injection technique without loss of any of the
analgesic effect.
Despite reduced fetal bupivacaine levels, several
significant changes in the FHR occurred after PCB
in the present series. In the whole group about
one-third of the blocks were associated with notice-
able changes. Our results do not agree with some
earlier studies reporting lack of FHR changes after
low dosage PCB [10, 12, 14]. Bradycardia lasting
on average for 8 minutes and starting 2—4 minutes
after PCB was observed at a 12% rate. TERAMO
[16], by using 100mg or 50 mg of bupivacaine,
found a 21 % frequency of bradycardia, HOLLMEN
[6] a rate of 30%, JÄGERHORN [10] a 10% rate
but MEIS [12] and REID [14] almost none. Com-
parison of FHR patterns after PCB are difficult
because most earlier studies have not been done
with direct FHR recording and also the criteria of
pathological and non-pathological FHR patterns,
e.g. bradycardia are not unambiguous. Late
decelerations in our study were observed in five
cases after PCB and mostly in association with
bradycardia as also noted in earlier reports [16].
Decreased FHR variability (silent pattern) was >
observed after 20% of the blocks which corre- |j
sponds to the findings of MEIS et al. [12]. The ·!
most frequent change in FHR after PCB in our |
material was the disappearance of FHR accelera- i
tions. The accelerations have been regarded as
a sensitive sign of fetal arousal level and non-
hypoxic state [7, 13]. Similar finding was also
reported by MEIS [12].
The fetal pH did not decrease on average after j
PCB but the fall was more pronounced in 3 cases
with bradycardia which is in accordance with the
findings of previous studies [16]. No universal
change in the mean uterine activity was noticed
after PCB, but in five cases demonstrating brady-
cardia three showed a prompt increase in uterine
contractions and in the baseline tone, which might
at least partly explain the change in the FHR
pattern.
The etiopathology of FHR "changes in connection
with PCB is obviously multifactorial [17]. Accord-
ing to our observations the most important factor
in these mechanisms seems to be the rapid trans-
placental passage of the local anesthetic agent
into the fetal circulation. Since we were not able
to show any decrease in placental blood flow
after PCB even in cases of fetal bradycardia,
the initial bradycardia obviously represents a
direct toxic effect of bupivacaine on the fetal
heart and on its regulatory centers. In vitro experi-
ments using uterine artery pieces show [3, 4] that
lidocaine can constrict these vessels for a con-
siderable time, when much higher concentrations
(400—1000 ug/ml) than seen in clinical practice
are used. Extrapolation of these results in vivo
conditions seems to be hardly applicable to human
studies. In ewes a direct injection of bupivacaine
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into the maternal aorta bringing about a plasma
concentration of 5 ug/ml results in hypertonus of
the uterus, fetal bradycardia and decreased uterine
blood flow [5]. These plasma concentrations are
very high and in the interpretation of these animal
studies it is difficult to determine which of the
parameters is the primary one. Disappearance of
FHR accelerations and decrease of FHR variability
observed in our study represent a direct pharma-
cological effect of bupivacaine at fetal level. These
kinds of changes are commonly seen after adminis-
tration of many other drugs used in labor, e.g.
pethidin (meperidine) [13]. Although there is
obviously some relation between pathological
FHR and fetal plasma concentration of the agent,
the most important factor may still be the pharma-
cokinetic properties of the anesthetic agent, i.e.
the rate of the rise of fetal drug concentration
after the block. Our universal observation was that
mothers with fetal bradycardia very rapidly
achieved analgesia after PCB. The superficial injec-
tion technique was initially developed to reduce
rapid absorption of the local anesthetic agent from
the paracervical space. It seems possible that even
after carefully applied blocks a rapid absorption of
the drug may sometimes occur leading to an
abrupt rise in blood concentrations and to fetal
FHR changes. This observation may signify that
the technique of PCB must be individually modi-
fied. Probably the best method to avoid rapid
absorption is according to our recent experience,
to maintain an interval of 10—15 minutes between
the application of anesthetic solution to each side
of the cervix.
Summary
Vasoconstriction of the uterine arteries, hypertonus
of the uterus, and the direct toxic effects of a local
anesthetic on the fetus or a combination of the above
have been presented as etiological factors of fetal brady-
cardia following paracervical block. The reduce fetal side-
effects a superficial and lowdosage technique of PCB have
been advocated. We have studied the effects of 25 mg of
bupivacaine PCB using the above technique on fetal
heart rate pattern (FHR), fetal acid-base balance, uterine
activity, placental blood flow and maternal and fetal
plasma levels of bupivacaine in 38 patients.
The analgesic effect of a single 25 mg of bupivacaine PCB
was good in 76 %, moderate in 12% and poor in 12% of
the cases. No changes in maternal heart rate or in blood
pressure were noted. Fetal bradycardia defined as a
decrease of mean fetal heart rate of at least 20 bpm or an
absolute rate less than 100 bpm and a duration greater
than two minutes occurred in 12 % of the cases. The mean
amplitude of the baseline fetal heart rate variability
decreased significantly after PCB and a silent pattern (an
amplitude less than 5 bpm) was observed in 20 % of the
cases. The most frequent (27%) pathological finding in
our study was the disappearance of FHR accelerations
after PCB. Similarly early and late decelerations of FHR
occurred more often after PCB than during the control
period before the block. The fetal pH from scalp blood
samples did not, on avarage, decrease after PCB, but did
so in cases with fetal bradycardia.
Intervillous blood flow as measured by the 133Xe wash-
out method did not change when measured before and
after PCB. In addition in three cases with fetal brady-
cardia the changes in the intervillous blood flow were
minimal. No significant changes in the mean uterine tone,
amplitude and frequency of contractions were observed
after PCB. However, an obvious uterine hypertonus was
observed after PCB was observed in three cases of fetal
bradycardia but not in two other cases of bradycardia or
in the 8 cases of silent FHR pattern.
Mean maternal bupivacaine concentration 20 minutes
after PCB was 0.14 ± 0.06 ug/ml and 0.07 ± 0.04 ug/ml at
birth. Simultaneous fetal and umbilical venous and arterial
concentrations were correspondingly 0.04 ±0.02 ug/ml,
0.03 ± 0.01 ug/ml and 0.03 ± 0.01 ug/ml, and they were
significantly lower than respective maternal concentra-
tions.
It seems possible to decrease fetal and maternal levels of
bupivacaine by using a low dosage and superficial injec-
tion technique without loosing anything of the analgesic
effect. However, several significant changes in fetal heart
rate pattern can occur. About one third of the block were
associated with noticable FHR changes in the present
series. The etiopathology of FHR changes in connection
with PCB is obviously multifactorial. According to
our observations the most important factor in these
mechanisms seems to be the rapid transplacental passage
of the local anesthetic into fetal circulation. Since we
were not able to show any decrease of placental blood
flow after PCB even in cases with fetal bradycardia, the
initial bradycardia obviously represents a direct toxic
effect of bupivacaine on the regulatory centers of the
fetal heart rate. Disappearance of FHR accelerations and
the decrease of FHR variability observed in our study
represent a pharmacological effect of bupivacaine at fetal
level. In some cases uterine hypertonus following PCB
may be an additional etiological factor of fetal brady-
cardia.
It seems possible that even after carefully applied PCBs a
rapid absorption of the local anesthetic agent may some-
times occur leading to an abrupt rise in the fetal blood
concentrations and to fetal heart rate changes.
Keywords: Bupivacaine, paracervical block, fetal heart rate pattern, fetal pH, placental blood flow, plasma levels of
bupivacaine, uterine activity.
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Zusammenfassung
Wirkungen eines Paracervicalblocks mit Bupivacain in
niedriger Dosierung auf Mutter und Fet
Als ätiologische Faktoren einer fetalen Bradykardie nach
einem paracervikalen Block (PCB) werden die Vasokon-
striktion der uterinen Arterien, ein erhöhter Tonus des
Uterus, direkte toxische Wirkungen der lokalen Anästhe-
sie oder eine Kombination aller drei Effekte angesehen.
Durch eine oberflächliche Injektion einer niedrigen Dosis
glaubt man, die fetalen Nebenwirkungen beim PCB redu-
zieren zu können. Wir untersuchten die Wirkung eines
PCB mit 25 mg Bupivacain, in oben beschriebener Tech-
nik appliziert, auf die fetale Herzfrequenz (FHR), den
fetalen Säure-Basen-Status, die Uterusaktivität sowie die
Plazentadurchblutung und bestimmten die mütterlichen
und fetalen Bupivacain-Plasmaspiegel. Das Untersuchungs-
kollektiv bestand aus 38 Patientinnen.
Die analgesierende Wirkung eines PCB mit einer einzelnen
Bupivacaindosis von 25 mg war bei 76 % der Fälle gut, bei
12% mäßig und bei weiteren 12% schlecht. Die mütter-
liche Herzfrequenz sowie der Blutdruck blieben unver-
ändert. Eine fetale Bradykardie, definiert als ein Abfall
der mittleren Herzfrequenz um mindestens 20 bpm oder
eine absolute Frequenz von weniger als 100 bpm bei einer
Dauer von mehr als 2 Minuten, ereignete sich in 12% der
Fälle. Die mittlere Amplitude der basalen FHR-Variabifi-
tät nahm nach dem PCB signifikant ab; silente Verläufe
(Amplitude unter 5 bpm) wurden in 20 % der Fälle
beobachtet. Der häufigste pathologische Befund (27%)
in unserer Untersuchung war das Sistieren der FHR-
Akzelerationen nach dem PCB. Ebenso fanden sich
Früh- und Spätdezelerationen der FHR nach dem PCB
häufiger als in der Kontrollphase vor dem Block. Der
fetale pH im Skalpblut zeigte im Schnitt keinen Abfall
nach dem PCB; ein Abfall erfolgte jedoch bei den Feten
mit Bradykardien.
Die Durchblutung im intervillösen Raum, gemessen mit
der 133Xe-Auswaschmethode, zeigte nach dem PCB keine
Veränderung gegenüber der Kontrolle vorher. Es muß aber
hinzugefügt werden, daß in 3 Fällen mit fetaler Brady-
kardie minimale Veränderungen des intervillösen Blut-
flusses registriert werden konnten. Hinsichtlich der mitt-
leren Tonisierung des Uterus sowie der Amplitude und
Häufigkeit der Kontraktionen haben wir keine signifikan-
ten Veränderungen nach dem PCB beobachtet. Jedoch
ließ sich in 3 Fällen mit fetaler Bradykardie ein deutlich
gesteigerter uteriner Tonus feststellen, während in 2
weiteren Fällen mit Bradykardie sowie in 8 Fällen mit
silenten FHR-Mustern diese Veränderung ausblieb.
Die mittlere Bupivacain-Konzentration im mütterlichen
Blut betrug 20 Minuten nach dem PCB 0,14 ± 0,06 Mg/ml
und zum Zeitpunkt der Geburt 0,07 ± 0,04 Mg/ml. Simul-
tane Messungen im fetalen Blut sowie im venösen und
arteriellen Nabelblut ergaben Konzentrationen von
0,04 ± 0,02Mg/ml, 0,03 ± 0,01 Mg/ml und 0,03 ± 0,01 Mg/ml
und lagen damit signifikant niedriger als die mütterlichen
Konzentrationen.
Es scheint möglich zu sein, die fetalen und mütterlichen
Bupivacainspiegel durch eine niedrige Dosis und eine ober-
flächliche Injektionstechnik zu senken, ohne die analge-
sierende Wirkung zu reduzieren. Jedoch können einige
wichtige Veränderungen des FHR-Musters auftreten. In
unserer Untersuchungsreihe war ein Drittel der Blocks mit
ernstzunehmenden FHR-Veränderungen assoziiert, deren
Ätiologie im Zusammenhang mit dem PCB offensichtlich
multifaktoriell ist. In Übereinstimmung mit unseren
Beobachtungen wird der rasche transplazentare Transport
des Lokalanästhetikums in den fetalen Kreislauf als der
wichtigste Faktor angesehen. Da wir selbst bei fetalen
Bradykardien nach dem PCB keine herabgesetzte Pla-
zentadurchblutung nachweisen konnten, ist die initiale
Bradykardie offensichtlich Folge eines direkten toxischen
Effektes des Bupivacains auf die Regulationszentren des
fetalen Herzens. Das Sistieren der FHR-Akzelerätionen
sowie der Abfall der FHR-Variabilität, die wir in unserer
Untersuchung beobachtet haben, spiegeln die pharma-
kologische Wirkung auf fetalem Niveau wieder. In einigen
Fällen mag der gesteigerte uterine Tonus ein zusätzlicher
ätiologischer Faktor bei der fetalen Bradykardie sein.
Offensichtlich kann selbst nach sorgfältig gesetzen PCB's
manchmal eine rasche Resorption des Lokalanästhetikums
erfolgen, die dann zu einem, plötzlichen Anstieg des
fetalen Bupivacain-Spiegels und damit zu FHR-Verände-
rungen führt.
Schlüsselwörter: Bupivacain, Bupivacain-Spiegel, fetale Herzfrequenz, fetaler pH, paracervikaler Block, Plazentadurch-
blutung, Uterusaktivität.
Resume
Effets du bloc para-cervical ä la bupivacaine ä faible dose
sur la mere et le foetus
On a incrimine la vasoconstriction des arteres utorines,
l'hypertonie uterine, et les effets toxiques directs sur le
foetus d'une anesthesie locale ou l'association de ces
elements comme facteurs etiologiques de la bradycardie
foetale survenant apres bloc para°-cervical. On a proposo
une technique de BPC superficiel et ä faible dose afin de
reduire les effets secondaires sur le foetus. Nous avons
etudie les·effets du bloc para-cervical effectue selon la
technique ci-dessus avec 25 mg de bupivacame sur le
rythme cardiaque foetal (RCF), l'equilibre acido-basique
foetal, 1'activite uterine, le debit sanguin placentaire et les
concentrations plasmatiques foetales et maternelles de
bupivaca'ine chez 38 patientes.
L'effet analgesique d'ün BPC utilisant l dose unique de
25 mg de bupivacaine a ete bon dans 76 % des cas, moyen
dans 12 % et faible dans 12 %. On n'a pas mis en evidence
de modifications de la frequence cardiaque maternelle ni
de la pression arterielle. Dans 12% des cas est survenue
une bradycardie foetale, definie par une diminution
pendant au rnoins 2 minutes du rythme cardiaque foetal
J.Perinat.Med. 12(1984)
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moyen d'au moins 20 bpm ou une frequence absolue
inferieure ä 100 bpm pendant au moins 2 minutes.
L'amplitude moyenne de l'instabilite de base du rythme
cardiaque foetal diminue de fagon significative apres BPC
et un rythme plat (avec une amplitude inferieure ä 5 bpm)
s'observe dans 20% des cas. L'element pathologique le
plus frequent (27%) trouve dans notre etude est la
disparition des accelerations du RCF apres BPC. De
meme, des decelerations precoces et tardives du RCF
surviennent plus souvent apres BPC que durant la periode
temoin avant le bloc. Le pH foetal analyse ä partir de
prelevements au scalp ne diminue pas en moyenne apres
BPC, mais chute en cas de bradycardie foetale. Le debit
sanguin intervilleux determine par la methode de dilution
au 133 Xe ne subit pas de modification s'il est mesure
avant et apres BPC. De plus, dans 3 cas de bradycardie
foetale, les modifications du debit sanguin intervilleux
ont ete minimes. On n'a pas observe de modifications
significatives du tonus uterin de base, ni dans l'amplitude
et la frequence des contractions uterines apres BPC.
Cependant, une hypertonie uterine reelle a ete observee
apres BPC dans 3 cas de bradycardie foetale mais non
dans les 2 autres cas de bradycardie ni dans les 8 cas de
rythmes plats.
Les concentrations maternelles moyennes de bupivacaine
ont ete de 0,14 ± 0,06 ug/ml 20 minutes apres BPC et de
0,07 ± 0,04 ug/ml ä la naissance. Les concentrations
simultanees foetales et ombilicales correspondantes
(arterielles et veineuses) etaient de 0,04 ± 0,02 ug/ml;
0,03 ± 0,01 ug/ml et de 0,03 ± 0,01 ug/ml, ce qui est
significativement inferieur aux concentrations maternelles
correspondantes.
II semble possible de diminuer les taux maternels et
foetaux de bupivacaühe en utilisant de faibles doses et une
technique d'injection superficielle sans perdre en anal-
gesie. Neanmoins, plusieurs modifications significatives du
rythme cardiaque foetal peuvent se produire. Environ 1/3
des blocs se sont accompagnes de modifications notables
du RCF dans cette serie. L'etiopathologie des modifica-
tions du RCF en liaison avec le BPC est objectivement
multifactorielle. Selon nos observations, le facteur le plus
important dans ces mecanismes semble etre le passage
transplacentaire rapide de l'anesthesique local dans la
circulation foetale. Toutefois, il ne nous a pas ete possible
de montrer une diminution du flux sanguin placentaire
apres BPC meme lor s de brady car dies foetales, la brady-
cardie initiale represente objectivement un effet toxique
direct de la bupivacaine sur les centres regulateurs du
rythme cardiaque foetal. La disparition des accelerations
et la diminution de Tinstabilite du RCF observees dans
notre etude sont le temoin d'un effet pharmacologique de
la bupivacaine aux taux foetaux. Dans quelques cas,
1'hypertonie uterine apres BPC peut etre un facteur
etiologique supplemental de la bradycardie foetale.
II semble possible que meme apres un BPC realise avec
soin, une absorption rapide du produit anesthesique local
puisse parfois se produire entrainant une elevation brutale
des concentrations sanguines foetales et des modifications
du rythme cardiaque foetal.
Mots-cles: Activite uterine, bloc para-cervical, bupivacaine, debit sanguin placentaire, pH foetal, rythme cardiaque
foetal, taux plasmatiques de bupivacaine.
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